History of Benzodiazepine Prescriptions and Risk of Dementia: Possible Bias Due to Prevalent Users and Covariate Measurement Timing in a Nested Case-Control Study
Open accessThe DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Previous estimates of whether long-term exposure to benzodiazepines increases dementia risk are conflicting and are compromised by the difficulty of controlling for confounders and by reverse causation. We investigated how estimates for the association between benzodiazepine use and later dementia incidence varied based on study design choices, using a case-control study nested within the United Kingdom’s Clinical Practice Research Datalink. A total of 40,770 dementia cases diagnosed between April 2006 and July 2015 were matched on age, sex, available data history, and deprivation to 283,933 control subjects. Benzodiazepines and Z-drug prescriptions were ascertained in a drug-exposure period 4–20 years before dementia diagnosis. Estimates varied with the inclusion of new or prevalent users, with the timing of covariate ascertainment, and with varying time between exposure and outcome. There was no association between any new prescription of benzodiazepines and dementia (adjusted odds ratio (OR) = 1.03, 95% confidence interval (CI): 1.00, 1.07), whereas an inverse association was observed among prevalent users (adjusted OR = 0.91, 95% CI: 0.87, 0.95), although this was likely induced by unintentional adjustment for colliders. By considering the choice of confounders and timing of exposure and covariate measurement, our findings overall are consistent with no causal effect of benzodiazepines or Z-drugs on dementia incidence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hypnotic use might increase risks although this is unclear and a 2018 study139 suggests that findings of a connection were related to reverse causality and confounders.”
From Dementia prevention, intervention, and care: 2020 report of the Lancet Commission (2020) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple imputation using chained equations: Issues and guidance for practice
White, I. R., Royston, P., & Wood, A. M. (2011) · Statistics in Medicine · doi:10.1002/sim.4067 · Cited by 9,792 · cited 1×
“body mass index, harmful alcohol use and smoking (37) (see Web Appendix for details of”
BackgroundDementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072 · cited 3×
“Potential confounders were identified as any known or suspected risk factors for dementia (3, 33) or predictors of benzodiazepine initiation (34, 35).”
Background2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Equivalence of the Mediation, Confounding and Suppression Effect
MacKinnon, D. P., Krull, J. L., & Lockwood, C. M. (2000) · Prevention Science · doi:10.1023/a:1026595011371 · Cited by 4,188 · cited 1×
“Together, these factors make the theoretical identification of confounding from mediating or colliding variables, as is often suggested (23, 24), difficult.”
BackgroundData Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 1×
“CPRD consists of anonymized electronic health records of 17 million patients from 719 general practices and is representative of age, sex, and ethnicity of the United Kingdom population (29).”
BackgroundBy the American Geriatrics Society 2015 Beers Criteria Update Expert Panel (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13702 · Cited by 2,609
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
Self-citationOveradjustment bias and unnecessary adjustment in epidemiologic studies.
Schisterman, E. F., Cole, S. R., & Platt, R. W. (2009) · Epidemiology · doi:10.1097/ede.0b013e3181a819a1 · Cited by 2,096 · cited 1×
“Measuring covariates recorded only up to the start of an exposure window (possibly years before exposure) risks missing confounders and omitted variable bias, whereas including covariates recorded during or after the exposure window (hence, after the exposure) risks underestimation through unintended adjustment formed…”
BackgroundBaumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660 · cited 1×
“Potential confounders were identified as any known or suspected risk factors for dementia (3, 33) or predictors of benzodiazepine initiation (34, 35).”
BackgroundEvaluating medication effects outside of clinical trials: new-user designs
Ray, W. A. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg231 · Cited by 1,646
2015 Alzheimer's disease facts and figures
Alzheimer's Association (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.003 · Cited by 1,635
Hernan, M. A. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.2.176 · Cited by 1,445 · cited 1×
“colliding variables, as is often suggested (23, 24), difficult.”
BackgroundTriangulation in aetiological epidemiology
Lawlor, D. A., Tilling, K., & Davey Smith, G. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyw314 · Cited by 1,129 · cited 1×
“Given the inherent difficulty of measuring confounders and of separating confounding from mediating or colliding effects in these cases, the aim for observational studies should not necessarily be to provide single unbiased effect estimates, but such studies can provide robust upper or lower bounds on effect sizes, de…”
BackgroundHernán, M. A., Sauer, B. C., Hernández-Díaz, S., Platt, R., & Shrier, I. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.04.014 · Cited by 1,097 · cited 2×
“time-lag between exposure and outcomes (19, 20).”
BackgroundLombardo, I., Ramaswamy, G., Piscitelli, S. C., & Friedhoff, L. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.08.154 · Cited by 656
Benzodiazepine use and risk of Alzheimer's disease: case-control study
Billioti de Gage, S., Moride, Y., Ducruet, T., Kurth, T., Verdoux, H., Tournier, M., Pariente, A., & Begaud, B. (2014) · BMJ · doi:10.1136/bmj.g5205 · Cited by 558 · cited 1×
“In a study based on a Canadian insurance claims database, a significant association was reported with a dose-response relationship (15).”
BackgroundIncreasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013
Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016) · American Journal of Public Health · doi:10.2105/ajph.2016.303061 · Cited by 531 · cited 1×
“If true, this is an important opportunity to prevent dementia, because 9% of older US adults currently use benzodiazepines, with 31%of these being long-term users (5, 6).”
BackgroundAnticholinergic drugs and risk of dementia: case-control study
Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A., Myint, P. K., Grossi, C. M., Mattishent, K., Bennett, K., et al. (2018) · BMJ · doi:10.1136/bmj.k1315 · Cited by 520 · cited 1×
“a wider project estimating the associations of drug use on dementia incidence (27), and have explored several of these issues.”
BackgroundSelf-citationBenzodiazepine use and risk of dementia: prospective population based study
Billioti de Gage, S., Begaud, B., Bazin, F., Verdoux, H., Dartigues, J.-F., Peres, K., Kurth, T., & Pariente, A. (2012) · BMJ · doi:10.1136/bmj.e6231 · Cited by 436
Tannenbaum, C., Paquette, A., Hilmer, S., Holroyd-Leduc, J., & Carnahan, R. (2012) · Drugs & Aging · doi:10.1007/bf03262280 · Cited by 241
Gray, S. L., Dublin, S., Yu, O., Walker, R., Anderson, M., Hubbard, R. A., Crane, P. K., & Larson, E. B. (2016) · BMJ · doi:10.1136/bmj.i90 · Cited by 233 · cited 2×
“(17) reported a small association among low users that was not observed when the lag period was extended beyond 2 years, again suggesting no causal link.”
BackgroundNicholls, S. G., Quach, P., von Elm, E., Guttmann, A., Moher, D., Petersen, I., Sørensen, H. T., Smeeth, L., Langan, S. M., & Benchimol, E. I. (2015) · PLOS ONE · doi:10.1371/journal.pone.0125620 · Cited by 217 · cited 1×
“This manuscript has been prepared according to the Reporting of Studies Conducted Using Observational Routinely Collected Data guidelines (28).”
MethodThe Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis
Crowe, S. F., & Stranks, E. K. (2018) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx120 · Cited by 209
Application of lag‐time into exposure definitions to control for protopathic bias
Tamim, H., Monfared, A. A. T., & LeLorier, J. (2007) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1360 · Cited by 186 · cited 1×
“time-lag between exposure and outcomes (19, 20).”
Aminzadeh, F., Molnar, F. J., Dalziel, W. B., & Ayotte, D. (2012) · Canadian Geriatrics Journal · doi:10.5770/cgj.15.42 · Cited by 186 · cited 1×
“We defined a drug-exposure period (DEP) for each case/control group as the period starting after 1 year of up-to-standard data recorded, and at most 20 years before the index date, and ending 4 years before the index date (Web Figure 1) (31).”
MethodWu, C., Wang, S.-C., Chang, I., & Lin, K. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181a65210 · Cited by 166 · cited 1×
“In 2 studies that did not apply any lag between exposure and outcome, causal effect likely was overestimated (14, 16).”
BackgroundImfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2015) · Drug Safety · doi:10.1007/s40264-015-0319-3 · Cited by 112 · cited 2×
“significant association with benzodiazepine or Z-drug use and risk of dementia (18), also”
BackgroundBenzodiazepines and risk of all cause mortality in adults: cohort study
Patorno, E., Glynn, R. J., Levin, R., Lee, M. P., & Huybrechts, K. F. (2017) · BMJ · doi:10.1136/bmj.j2941 · Cited by 98 · cited 1×
“Potential confounders were identified as any known or suspected risk factors for dementia (3, 33) or predictors of benzodiazepine initiation (34, 35).”
BackgroundPenninkilampi, R., & Eslick, G. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0535-3 · Cited by 97 · cited 2×
“benzodiazepines use could increase dementia risk (4).”
BackgroundBenzodiazepine, psychotropic medication, and dementia: A population‐based cohort study
Shash, D., Kurth, T., Bertrand, M., Dufouil, C., Barberger‐Gateau, P., Berr, C., Ritchie, K., Dartigues, J., Bégaud, B., Alpérovitch, A., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.10.006 · Cited by 94 · cited 1×
“However, authors of previous studies examining benzodiazepine use and dementia incidence reported only slightly smaller associations with prevalent use compared with new use (14, 39).”
BackgroundLunt, M., Solomon, D., Rothman, K., Glynn, R., Hyrich, K., Symmons, D. P. M., Sturmer, T., & the British Society for Rheumatology Biologics Register, T. B. S. F. R. B. R. C. C. C. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwn391 · Cited by 90 · cited 1×
“The impact of each covariate was measured by the change in the log of the odds ratio induced by adding that covariate to a model only including the exposure stratified into new and prevalent use (36).”
BackgroundMartinez, C., Jones, R. W., & Rietbrock, S. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002080 · Cited by 89 · cited 1×
“This 4-year lag reduces the risk of protopathic bias, because the use of benzodiazepines in this period may be a marker of undiagnosed dementia (32).”
BackgroundTannenbaum, C., Paquette, A., Hilmer, S. N., Holroyd-Leduc, J. M., & Carnahan, R. M. (2012) · Drugs & Aging · doi:10.2165/11633250-000000000-00000 · Cited by 82
From bad to worse: collider stratification amplifies confounding bias in the “obesity paradox”
Banack, H. R., & Kaufman, J. S. (2015) · European Journal of Epidemiology · doi:10.1007/s10654-015-0069-7 · Cited by 72 · cited 1×
“, common consequences of the exposure and the outcome) will introduce bias rather than reduce it (25).”
BackgroundVandenbroucke, J., & Pearce, N. (2015) · American Journal of Epidemiology · doi:10.1093/aje/kwv225 · Cited by 67 · cited 1×
“This is particularly true for those with very long-term use, who may be most at risk (22).”
BackgroundBiétry, F. A.-M., Pfeil, A. M., Reich, O., Schwenkglenks, M. M., & Meier, C. R. (2017) · CNS Drugs · doi:10.1007/s40263-016-0404-x · Cited by 61 · cited 1×
“A Swiss study also reported no association between benzodiazepine prescriptions and new dementia medication prescriptions, despite only allowing a two year lag period (38).”
BackgroundMarra, E. M., Mazer‐Amirshahi, M., Brooks, G., van den Anker, J., May, L., & Pines, J. M. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13666 · Cited by 47 · cited 1×
“of guidance advising against long-term benzodiazepine use owing to side effects, addiction and tolerance (7), there has been no decline in their use in the past decade in the US (8-10), while a small decline in the UK has been accompanied by greater use of benzodiazepinerelated drugs including zopiclone, eszopiclone (…”
BackgroundSedative Load and Frailty Among Community-Dwelling Population Aged ≥65 Years
Peklar, J., O’Halloran, A. M., Maidment, I., Henman, M. C., Kenny, R. A., & Kos, M. (2014) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2014.10.010 · Cited by 45 · cited 2×
“and lead to tolerance (6), prescribers should to follow guidelines on avoiding or limiting their”
BackgroundSelf-citationNakafero, G., Sanders, R., Nguyen‐Van‐Tam, J. S., & Myles, P. R. (2016) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4028 · Cited by 32 · cited 1×
“Potential confounders were identified as any known or suspected risk factors for dementia (3, 33) or predictors of benzodiazepine initiation (34, 35).”
BackgroundMcMaster, M., Fielding, E., LIM, D. J., Moyle, W., & Beattie, E. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217002447 · Cited by 32 · cited 1×
“of guidance advising against long-term benzodiazepine use owing to side effects, addiction and tolerance (7), there has been no decline in their use in the past decade in the US (8-10), while a small decline in the UK has been accompanied by greater use of benzodiazepinerelated drugs including zopiclone, eszopiclone (…”
BackgroundHeßmann, P., Dodel, R. C., Baum, E., Müller, M., Paschke, G., Kis, B., Zeidler, J., Klora, M., Reese, J., & Balzer‐Geldsetzer, M. (2018) · Pharmacopsychiatry · doi:10.1055/s-0044-100523 · Cited by 12 · cited 1×
“of guidance advising against long-term benzodiazepine use owing to side effects, addiction and tolerance (7), there has been no decline in their use in the past decade in the US (8-10), while a small decline in the UK has been accompanied by greater use of benzodiazepinerelated drugs including zopiclone, eszopiclone (…”
Background
Cited by
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430
“143 When benzodiazepine use was considered, in one study, sleep length was no longer significant 139 but not in all studies.”
Self-citationRetractedInnes, K. E., & Sambamoorthi, U. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200960 · Cited by 92
Santabárbara, J., Lipnicki, D. M., Olaya, B., Villagrasa, B., Bueno‐Notivol, J., Nuez, L., López‐Antón, R., & Gracia‐García, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061791 · Cited by 89
“However, these results are controversial [60,61] and future studies are warranted to further investigate the role of benzodiazepine intake and risk of dementia.”
The cognitive effect of anticholinergics for patients with overactive bladder
Welk, B. K., Richardson, K., & Panicker, J. N. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00504-x · Cited by 82
Self-citationAnticholinergic and benzodiazepine medication use and risk of incident dementia: a UK cohort study
Grossi, C. M., Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A. J., Myint, P. K., Campbell, N. L., Boustani, M. A., et al. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1280-2 · Cited by 64
Self-citation
Metadata
- Authors
- Richardson, K., Mattishent, K., Loke, Y. K., Steel, N., Fox, C., Grossi, C. M., Bennett, K., Maidment, I., Boustani, M., Matthews, F. E., Myint, P. K., Campbell, N. L., Brayne, C., Robinson, L., & Savva, G. M.
- Affiliations
- University of East Anglia (GB)
- Royal College of Surgeons in Ireland (IE)
- Newcastle University (GB)
- University of Aberdeen (GB)
- Purdue University West Lafayette (US)
- University of Cambridge (GB)
- Corresponding author
- Richardson, Kathryn
- ORCID
- Venue
- American Journal of Epidemiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-03-27
- Volume
- 188
- Issue
- 7
- Pages
- 1228-1236
- ISSN
- 0002-9262 (ISSN-L)
- 1476-6256
- PMC
- PMC6601519
- OpenAlex
- W2918471623
- Cited by
- 36
- References
- 41
- Citations by year
- 2025: 3 · 2024: 3 · 2023: 4 · 2022: 2 · 2021: 9 · 2020: 12 · 2019: 3
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- American Journal of Epidemiology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Aston Publications Explorer (Aston University) (acceptedVersion)
- UEA Digital Repository (University of East Anglia) (acceptedVersion)
- Aberdeen University Research Archive (Aberdeen University) (submittedVersion, cc-by-nc)
- Repository@Hull (Worktribe) (University of Hull) (submittedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- UK Alzheimer’s Society (AS-PG-2013-017)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Epidemiology
- Keywords
- benzodiazepines, dementia risk, Z-drugs, long-term drug exposure, reverse causality, collider bias, confounding adjustment, dementia incidence
- MeSH terms
- Aged, Benzodiazepines, Dementia, Female, United Kingdom, Humans, Male, Drug Prescriptions, Risk Factors, Bias, Incidence, Prevalence, Case-Control Studies, Databases, Factual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.